Catheter-Directed Thrombolysis Promising for Intermediate-Risk Pulmonary Embolism
A modified reperfusion protocol for intermediate-risk pulmonary embolism (PE) seemed to work without causing excessive bleeding in the small randomized CANARY trial. Use of conventional catheter-directed thrombolysis (CDT) with alteplase led to 4.3% of patients showing right ventricular (RV) recovery at 3 months (in terms of echocardiographic RV/LV ratios >0.9), which was numerically, but not […]
MRI-Guided HIFU Effective in Intermediate-Risk Prostate Cancer
MRI-guided high-intensity focused ultrasound (HIFU) is effective in patients with intermediate-risk prostate cancer, researchers reported. According to the team’s multicenter, single-arm, phase IIb study of 101 patients who received the treatment, 96% had no evidence of grade group 2 or higher prostate cancer on 6-month MRI-targeted and systematic biopsy in the treated area of the […]
Xtandi During AS Reduced Progression Risk in Early Prostate Cancer
Patients with low- or intermediate-risk localized prostate cancer who received enzalutamide (Xtandi) monotherapy saw a reduced risk of cancer progression, according to a randomized phase II trial. Among 227 patients on active surveillance (AS), treatment with enzalutamide reduced the risk of pathological or therapeutic prostate cancer progression by 46% compared with AS alone (HR 0.54, […]